Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway

HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway

US Patent 9758552 · Granted Sep 12, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Dihydroquinazolinones exhibiting protective activity against intracellular-actin2024
3-methylcrotonic acid decarboxylase (MDC) variants2022
Benzodiazepine derivatives for use in the treatment of Chlamydiales infections2021
3-methylcrotonic acid decarboxylase (MDC) variants2021
3-methylcrotonic acid decarboxylase (MDC) variants2020
Immunogenic peptides of the cyclin B1 tumor antigen2020
Adamantane or pinene derivatives for use in the treatment of chlamydiales infect2018
Method for real-time measurement of the individual secretions of a cell2017
CD4+ T survivin epitopes and uses thereof2017
2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral in2017
Quinazolinone derivatives for use in the treatment of chlamydiales infections2017
Compounds having a protective activity against toxins with intracellular activit2017